Gevokizumab
Gevokizumab
Gevokizumab (pronounced: jeh-voh-kih-zoo-mab) is a monoclonal antibody designed for the treatment of inflammatory and autoimmune diseases.
Etymology
The name "Gevokizumab" is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The suffix "-mab" is used for monoclonal antibodies, "kizo" refers to the immunomodulating properties of the drug, and "gevo" is a unique stem that doesn't carry a specific meaning.
Mechanism of Action
Gevokizumab works by binding to and inhibiting the action of interleukin-1 beta, a protein that plays a key role in the inflammatory response of the immune system. By blocking the action of interleukin-1 beta, Gevokizumab can reduce inflammation and the symptoms of diseases caused by excessive inflammation.
Clinical Uses
Gevokizumab has been investigated for use in a number of diseases, including Behcet's disease, non-infectious uveitis, and rheumatoid arthritis. However, as of 2021, it has not been approved for use by any major regulatory authority.
Related Terms
External links
- Medical encyclopedia article on Gevokizumab
- Wikipedia's article - Gevokizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski